14 hrs ago
AstraZeneca raises earnings outlook as sales climb
British-Swedish drugmaker AstraZeneca, which fought off a takeover from Pfizer earlier this year, raised its 2014 earnings outlook on Thursday and posted rising second-quarter sales.
Wed Jul 30, 2014
Vanguard Health Care Fund's Top Second Quarter Stocks
Over the duration of the second quarter the Vanguard Health Care Fund purchased added four new stocks to its holdings.
The Daily Caller
Selena Gomez Shows Off Skin In Snakeskin Halter Top
The movie, which has the same producer as the 1999 classic "Ten Things I Hate About You," premieres Aug. 1. Meanwhile, Justin Bieber was getting swung on by Orlando Bloom .
Tue Jul 29, 2014
European Commission Approves Eliquis for the Treatment of Deep Vein Thrombosis and Pulmonary Embolism
Bristol-Myers Squibb and Pfizer announced that the European Commission has approved Eliquis for the treatment of DVT and PE, and the prevention of recurrent DVT and PE in adults.
Mon Jul 28, 2014
Bristol-Myers Squibb and Ono Pharmaceutical Collaborate on Immunotherapies
Bristol-Myers Squibb and Ono Pharmaceutical signed a collaboration agreement to jointly develop and commercialize multiple immunotherapies as single agents and combination regimens to help address the unmet medical needs of patients with cancer in Japan, South Korea, and Taiwan.
Fri Jul 25, 2014
Bristol-Myers Squibb Company Taps Bay Area's Redwood City For...
Bristol-Myers Squibb Company Taps Bay Area's Redwood City For Expansion, Pharma Giant To Increase Workforce July 25, 2014 By Renee Morad , BioSpace.com Breaking News Staff Bristol-Myers Squibb Co.
Thu Jul 24, 2014
Bristol-Myers Squibb Company Appoints As India Country Head
Bristol-Myers Squibb India appointed Jitendra Tyagi as the BMS India country head.
Wed Jul 23, 2014
Customer Interaction Solutions
Bristol-Myers Squibb and Ono Pharmaceutical Co., Ltd. Announce...
Ono Pharmaceutical Co., Ltd. have signed a strategic collaboration agreement to jointly develop and commercialize multiple immunotherapies as single agents and combination regimens to help address the unmet medical needs of patients with cancer in Japan, South Korea and Taiwan.
The Motley Fool
Earnings Preview: Bristol-Myers Squibb and Celgene Corporation
Most health care stocks have been experiencing a roller coaster ride so far this year.
Forbes Earnings Preview: Bristol Myers Squibb
Bristol Myers Squibb reports its second-quarter earnings on Thursday, July 24, 2014, and the consensus earnings per share estimate is 45 cents per share.
Thu Jul 10, 2014
Bristol-Myers Squibb Makes Plans to Submit Biologics License Application for OpdivoA
Bristol-Myers Squibb Company today announced that, following discussions with the U.S. Food and Drug Administration , the company is planning a third quarter submission of a Biologics Licensing Application for OpdivoA for previously treated advanced melanoma.
Tue Jul 08, 2014
Bristol-Myers Squibb Given New $55.00 Price Target at Leerink Swann
Leerink Swann's price objective would suggest a potential upside of 14.92% from the stock's previous close.
Mon Jul 07, 2014
Japan Approves First All-Oral, Interferon- and Ribavirin-Free...
Bristol-Myers Squibb Company announced today that the Japanese Ministry of Health, Labor and Welfare has approved Daklinza , a potent, pan-genotypic NS5A replication complex inhibitor , and Sunvepra , a NS3/4A protease inhibitor, providing a new treatment that can lead to cure for many patients in Japan who currently have no treatment options.
Health Data Management
Duke, Bristol-Myers Squibb Open Up Study Data
These areas, it says, will refine ICD-10 plans to minimize impacts on productivity and reimbursement.
Thu Jul 03, 2014
Bristol-Myers Squibb May Be Fast-Tracking Its Promising Cancer Drug
However, with the recent release of promising data and the early termination of the first batch of Phase 3 trials, the drug may hit the market sooner than expected.
Wed Jul 02, 2014
B-MS recalls CMO made injectable blood thinner after finding "visible particles"
Bristol Myers Squibb has recalled several batches of the injectable version of the blood thinner Coumadin made by its CMO, Pharmalucence.